{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:44:38Z","timestamp":1793835878577,"version":"4.6.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Tetanus that occurs outside the neonatal period is not a statutory reporting disease in many regions, and few countries have comprehensive surveillance systems. To assess the level and durability of vaccine-induced tetanus immunity in a healthy population in Zhejiang, where long-term population-based data on non-neonatal tetanus immunity remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A cross-sectional study was conducted in 2024 among 3,659 healthy individuals. Anti-tetanus toxoid IgG concentrations were measured by ELISA and expressed in IU\/mL. Population immunity was evaluated by geometric mean concentration (GMC), seropositivity (\u22650.01 IU\/mL), and seroprotection (\u22650.1 IU\/mL). Antibody persistence was estimated according to age- and dose-specific antibody profiles. Generalized additive models (GAMs) with smoothing functions for the time since last doses were used to model nonlinear antibody trajectories overall, gender, and by dose group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall Geometric Mean Concentration (GMC) of tetanus IgG antibodies was 0.064 IU\/mL, with seropositivity (\u22650.01 IU\/mL) and seroprotection (\u22650.1 IU\/mL) rates of 85.05% and 52.94%, respectively. GMC peaked at 0.175 IU\/mL in children aged 6\u201311 months, remained relatively high through 2 years of age, and then generally declined to 0.008 IU\/mL in adults aged 40\u201359 years. By dose, GMC increased from 0.013 IU\/mL in the 0-dose group to 0.156 IU\/mL in the 3-dose group, then declined after 4 and 5 doses. Seroprotection exceeded 89% after 2\u20133 doses. GAM-fitted trajectories showed a rapid post-vaccination peak followed by gradual waning, with antibody levels remaining above 0.1 IU\/mL for 8.81 years overall. Waning was slower in men than in women (7.87 vs. 6.66 years), and the estimated duration of seroprotection was 6.03, 12.86, and 3.07 years after three, four, and five doses, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>A high seropositivity rate does not necessarily indicate durable seroprotection against tetanus. Booster immunization strategies should incorporate both vaccination history and time since the last dose to sustain long-term protection.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1824381","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:05:44Z","timestamp":1779689144000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Population waning trajectories of vaccine-induced tetanus immunity in Zhejiang, China"],"prefix":"10.3389","volume":"17","author":[{"given":"Fuxing","family":"Chen","sequence":"first","affiliation":[{"name":"Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[{"name":"Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejiao","family":"Pan","sequence":"additional","affiliation":[{"name":"Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linling","family":"Ding","sequence":"additional","affiliation":[{"name":"Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanqing","family":"He","sequence":"additional","affiliation":[{"name":"Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Qi","sequence":"additional","affiliation":[{"name":"Institute of Immunization and Prevention, Zhejiang Center for Disease Control and Prevention","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199204854.003.070622","article-title":"Tetanus","volume":"393","author":"Yen","year":"2019","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2017.02.034","article-title":"Electronic address swi. Tetanus vaccines: WHO position paper, February 2017 - Recommendations","volume":"36","year":"2018","journal-title":"Vaccine"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6702a1","article-title":"Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"67","author":"Liang","year":"2018","journal-title":"MMWR Recomm Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-12-138","article-title":"The seroepidemiology of immunoglobulin G antibodies against pertussis toxin in China: a cross sectional study","volume":"12","author":"Zhang","year":"2012","journal-title":"BMC Infect Dis"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2011.07.018","article-title":"Seroprevalence of antibodies to pertussis and diphtheria among healthy adults in China","volume":"63","author":"Zhang","year":"2011","journal-title":"J Infect"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2020.1840253","article-title":"Decline of serologic immunity to diphtheria, tetanus and pertussis with age suggested a full life vaccination in mainland China","volume":"17","author":"Liu","year":"2021","journal-title":"Hum Vaccin Immunother"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.03.052","article-title":"Antitoxins for diphtheria and tetanus decline more slowly after vaccination with DTwP than with DTaP: a study in a Chinese population","volume":"32","author":"Wu","year":"2014","journal-title":"Vaccine"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.06.026","article-title":"Investigation of the baseline tetanus antibody level and its persistence in a military unit","volume":"39","author":"Tong","year":"2021","journal-title":"Vaccine"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-9624.2020.02.017","article-title":"Meta-analysis on tetanus antibody protection rate of healthy population born after 1978 in China","volume":"54","author":"Liu","year":"2020","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2147\/idr.s404747","article-title":"6084 Cases of adult tetanus from China: A literature analysis","volume":"16","author":"Gou","year":"2023","journal-title":"Infect Drug Resist"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3201\/eid2407.171928","article-title":"Integrated serologic surveillance of population immunity and disease transmission","volume":"24","author":"Arnold","year":"2018","journal-title":"Emerg Infect Dis"},{"key":"B12","unstructured":"The Immunological Basis for Immunization Series Module 3: Tetanus update 2018\n          \n          \n          \n          2018"},{"key":"B13","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1186\/s12916-022-02547-2","article-title":"SARS-CoV-2 infection, vaccination, and antibody response trajectories in adults: a cohort study in Catalonia","volume":"20","author":"Karachaliou","year":"2022","journal-title":"BMC Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.778243","article-title":"Previous COVID-19 infection and antibody levels after vaccination","volume":"9","author":"Ali","year":"2021","journal-title":"Front Public Health"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.1674-2397.2025.05.005","article-title":"Serological survey of tetanus antibody levels among healthy individuals in Karamay city of Xinjiang Uygur Automonous Region","volume":"18","author":"Wang","year":"2025","journal-title":"Chin J Clin Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10111806","article-title":"Seroepidemiology of tetanus among healthy people aged 1\u201359 years old in Shaanxi Province, China","volume":"10","author":"Zhang","year":"2022","journal-title":"Vaccines Bsl"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn112150-20241212-01002","article-title":"Tetanus antibody levels in healthy people in Henan Province from 2022 to 2023","volume":"59","author":"Liu","year":"2025","journal-title":"Zhonghua Yu Fang Yi Xue Za Zhi"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad598","article-title":"Serologic immunity to tetanus in the United States, National Health and Nutrition Examination Survey, 2015-2016","volume":"78","author":"Bampoe","year":"2024","journal-title":"Clin Infect Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12040378","article-title":"Diphtheria and tetanus immunity status among Greek adults: Results from a nationwide seroprevalence study","volume":"12","author":"Papagiannis","year":"2024","journal-title":"Vaccines Bsl"},{"key":"B20","first-page":"38","article-title":"Tetanus IgG antibody levels among healthy people in Jiangsu province, 2018","volume":"26","author":"Chen","year":"2020","journal-title":"Chin J Vaccines Immun"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.26444\/aaem\/182987","article-title":"Seroprevalence of IgG antibodies against tetanus toxoid among different age groups in Poland","volume":"31","author":"Smietanska","year":"2024","journal-title":"Ann Agric Environ Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.05.015","article-title":"Seroprotection against tetanus in the Italian general population","volume":"42","author":"Bagordo","year":"2024","journal-title":"Vaccine"},{"key":"B23","unstructured":"Piano nazionale di prevenzione vaccinale (PNPV) 2023-2025. [National Vaccination Prevention Plan (PNPV) 2023-2025]"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12822","article-title":"Adult vaccination against tetanus and diphtheria: the European perspective","volume":"187","author":"Weinberger","year":"2017","journal-title":"Clin Exp Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.46234\/ccdcw2021.270","article-title":"Childhood immunization schedule for national immunization program vaccines \u2013 China (Version 2021)","volume":"3","year":"2021","journal-title":"China CDC Wkly"},{"key":"B26","article-title":"Chinese expert consensus on tetanus immunization","volume":"56","year":"2018","journal-title":"Zhonghua wai ke za zhi Chinese J surgery"},{"key":"B27","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.vaccine.2017.02.034","article-title":"Tetanus vaccines: WHO position paper - February 2017","volume":"92","author":"mondiale de la Sant\u00e9","year":"2017","journal-title":"Wkly Epidemiol Rec"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1542\/peds.63.2.301","article-title":"Standard and special human immune serum globulins as therapeutic agents","volume":"63","author":"Stiehm","year":"1979","journal-title":"Pediatrics"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7883\/yoken.jjid.2018.222","article-title":"Epidemiological study of tetanus seropositivity levels in different age groups in Ankara Province, Turkey, 2017","volume":"72","author":"Sahan","year":"2019","journal-title":"Jpn J Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s43587-023-00379-0","article-title":"Insufficient epitope-specific T cell clones are responsible for impaired cellular immunity to inactivated SARS-CoV-2 vaccine in older adults","volume":"3","author":"Xiao","year":"2023","journal-title":"Nat Aging"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12040381","article-title":"Seroprevalence of diphtheria and tetanus immunoglobulin G among the general health population in Guangzhou, China","volume":"12","author":"He","year":"2024","journal-title":"Vaccines Bsl"},{"key":"B32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/trstmh\/tru167","article-title":"Sex-based differences in immune function and responses to vaccination","volume":"109","author":"Klein","year":"2015","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-cellbio-100616-060718","article-title":"Sex and gender differences in the outcomes of vaccination over the life course","volume":"33","author":"Flanagan","year":"2017","journal-title":"Annu Rev Cell Dev Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1136\/adc.2005.076109","article-title":"Evaluation of a diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b vaccine given concurrently with meningococcal group C conjugate vaccine at 2, 3 and 4 months of age","volume":"92","author":"Kitchin","year":"2007","journal-title":"Arch Dis Child"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2015.1012015","article-title":"Comparative assessment of immunization coverage of migrant children between national immunization program vaccines and non-national immunization program vaccines in East China","volume":"11","author":"Hu","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.09.060","article-title":"Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses","volume":"25","author":"Heininger","year":"2007","journal-title":"Vaccine"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.4161\/hv.6.2.10117","article-title":"Immunological persistence in 4\u20136 and 7\u20139 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV\/Hib","volume":"6","author":"Zinke","year":"2010","journal-title":"Hum Vaccin"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1824381\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:05:48Z","timestamp":1779689148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1824381\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2026.1824381"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1824381","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"article-number":"1824381"}}